Notable Runner: Is Codexis, Inc.’s Fuel For Real? The Stock Just Increased Again

Notable Runner: Is Codexis, Inc.'s Fuel For Real? The Stock Just Increased Again

The stock of Codexis, Inc. (NASDAQ:CDXS) is a huge mover today! About 120,367 shares traded hands or 76.71% up from the average. Codexis, Inc. (NASDAQ:CDXS) has risen 18.60% since March 15, 2016 and is uptrending. It has outperformed by 13.11% the S&P500.
The move comes after 6 months positive chart setup for the $192.81 million company. It was reported on Oct, 18 by Barchart.com. We have $13.25 PT which if reached, will make NASDAQ:CDXS worth $356.70 million more.

Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on November, 2. They expect $-0.14 earnings per share, down 207.69% or $0.27 from last year’s $0.13 per share. After $0.07 actual earnings per share reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts -300.00% negative EPS growth.

According to Zacks Investment Research, “Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing.”

Insitutional Activity: The institutional sentiment increased to 1.42 in Q2 2016. Its up 0.34, from 1.08 in 2016Q1. The ratio improved, as 14 funds sold all Codexis, Inc. shares owned while 12 reduced positions. 20 funds bought stakes while 17 increased positions. They now own 16.51 million shares or 13.83% more from 14.50 million shares in 2016Q1.
Baillie Gifford last reported 0.01% of its portfolio in the stock. Walleye Trading holds 1,123 shares or 0% of its portfolio. California State Teachers Retirement System last reported 0% of its portfolio in the stock. Tower Cap Ltd Limited Liability Company (Trc) has invested 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Rhumbline Advisers accumulated 0% or 30,458 shares. Essex Invest Mgmt Lc accumulated 147,015 shares or 0.1% of the stock. The Missouri-based Stifel Finance Corp has invested 0% in Codexis, Inc. (NASDAQ:CDXS). New York State Common Retirement Fund has 34,400 shares for 0% of their US portfolio. Blair William & Communication Il holds 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 24,922 shares. Bancorp Of New York Mellon, a New York-based fund reported 117,756 shares. Architects last reported 0% of its portfolio in the stock. Nationwide Fund Advsrs holds 0% or 20,988 shares in its portfolio. Jpmorgan Chase holds 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 786 shares. Dimensional Fund Advsr Ltd Partnership, a Texas-based fund reported 65,695 shares. Mufg Americas Holdings has 0% invested in the company for 1,282 shares.

Insider Transactions: Since August 3, 2016, the stock had 0 buys, and 5 insider sales for $1.31 million net activity. VIVO VENTURES VII – LLC also sold $474,624 worth of Codexis, Inc. (NASDAQ:CDXS) on Thursday, September 8. Another trade for 12,643 shares valued at $53,807 was made by KELLEY BERNARD J on Wednesday, August 24. $75,974 worth of shares were sold by WOLF DENNIS P on Friday, August 26.

More recent Codexis, Inc. (NASDAQ:CDXS) news were published by: Marketwatch.com which released: “Codexis Inc.” on April 22, 2010. Also Nasdaq.com published the news titled: “Michael Aldridge Joins Codexis as Senior Vice President, Corporate & Strategic …” on October 17, 2016. Seekingalpha.com‘s news article titled: “Can Codexis Maintain Its Clout?” with publication date: May 06, 2016 was also an interesting one.

CDXS Company Profile

Codexis, Inc., incorporated on January 31, 2002, is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s technologies enable scale-up and implementation of biocatalytic solutions for process development, from research to manufacturing. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing clients to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Firm have commercialized its technology and products in the pharmaceuticals market, which is its primary business focus. The Company’s pharmaceutical customers, including several of the global pharmaceutical companies, use its technology, services and products in their manufacturing processes and process development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment